Related Experiment Video
Updated: Mar 3, 2026
07:55
Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
Published on: October 17, 2015
12.4K
The Involvement of Post-Translational Modifications in Alzheimer's Disease
Serena Marcelli1,2, Massimo Corbo3, Filomena Iannuzzi1
1Laboratory of Pharmacology of Synaptic Disease, EBRI Rita Levi-Montalcini Foundation, Rome, Italy.
Current Alzheimer Research
|May 6, 2017
Summary
Post-translational modifications (PTMs) alter Alzheimer
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Alzheimer's disease (AD) is a leading cause of dementia in aging populations.
- AD pathology involves neuronal loss and hallmark protein aggregates: amyloid-beta plaques and neurofibrillary tangles.
- These hallmarks arise from complex molecular processes within brain cells.
Purpose of the Study:
- To explore the impact of post-translational modifications (PTMs) on Alzheimer's disease-related proteins.
- To understand how PTMs influence protein function and contribute to AD pathology.
- To investigate potential interactions between different PTMs in the context of AD.
Main Methods:
- Review of current literature on PTMs affecting AD-related proteins.
- Focus on specific PTMs including ubiquitination, phosphorylation, SUMOylation, acetylation, and nitrosylation.
- Analysis of how these modifications impact key AD proteins such as APP, Aβ, tau, and BACE1.
Main Results:
- PTMs significantly alter the function of proteins implicated in Alzheimer's disease.
- Aberrant protein modifications are linked to the onset and progression of AD.
- Specific PTMs like phosphorylation and ubiquitination play critical roles in AD pathogenesis.
Conclusions:
- Understanding PTMs offers insights into Alzheimer's disease mechanisms.
- Investigating PTMs and their interactions may reveal novel therapeutic targets for AD.
- Aberrant PTMs are a key factor in the development of Alzheimer's disease pathology.
Keywords:
Acetylation.AlzheimerNitrosylationPhosphorylationPost-translational modificationsSUMOylationUbiquitinatinMore Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
02:04Covalently Linked Protein Regulators
9.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
9.8K
03:03Amyloid Fibrils
12.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.2K
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:26Protein Modifications in the RER
7.3K
Modification of secretory and transmembrane proteins entering the rough ER begins in the ER lumen. These modifications aid in protein folding and stabilize the acquired tertiary structure. Protein modifications in the rough ER co-occur at different stages of protein folding.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
7.3K